Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
McKessonMEX:MCK 76 3-Year EBITDA Growth Rate is 14.40% as of Jun. 2026, which is 6% below its 10-year median of 15.40. GuruFocus rates MEX:MCK with a GF Score™ of 76/100 and a GF Value™ of MXN14,775.99 (Fairly Valued). The stock has 2 warning signs investors should review. Among 105 Medical Distribution companies, McKesson ranks better than 68.57% on this metric.
During the past 12 months, McKesson's average EBITDA Per Share Growth Rate was 49.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of McKesson was 297.20% per year. The lowest was -68.10% per year. And the median was 15.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
McKesson 3-Year EBITDA Growth Rate Related Terms
MEX:MCK vs COR, CAH, HSIC: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, McKesson's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
McKesson 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, McKesson's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where McKesson's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.40% mean?
McKesson (MEX:MCK) has a 3-Year EBITDA Growth Rate of 14.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for McKesson and its competitors. This is near median its historical median of 15.40. According to the industry distribution chart, McKesson ranks #33 out of 105 companies in the Medical Distribution industry, placing it in the top 31.4%.
Is McKesson's 3-Year EBITDA Growth Rate too high?
McKesson's current 3-Year EBITDA Growth Rate of 14.40% is near median its 10-year median of 15.40. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. McKesson's value of 14.40% is 166.7% above this industry median. Based on the distribution chart, McKesson ranks #33 out of 105 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, McKesson has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does McKesson's 3-Year EBITDA Growth Rate compare to COR and CAH?
According to the Medical Distribution industry distribution chart, McKesson ranks #33 out of 105 companies for 3-Year EBITDA Growth Rate. This puts McKesson in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.40. McKesson's value of 14.40% is 166.7% above this benchmark. While the company's 10-year median is 15.40 vs. the industry median of 5.40, McKesson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. McKesson's current 3-Year EBITDA Growth Rate of 14.40% is 166.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for McKesson and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. McKesson's current 3-Year EBITDA Growth Rate is 14.40%, which is near median its own 10-year median of 15.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is McKesson stock overvalued right now?
Based on GuruFocus' analysis, McKesson (MEX:MCK) is currently considered Fairly Valued. The stock's GF Value™ is MXN14,775.99, compared to a current price of MXN15,800.00 — trading 6.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.40%, which is near median its 10-year median of 15.40 and 166.7% above the Medical Distribution industry median of 5.40. McKesson's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For McKesson (MEX:MCK), the current 3-Year EBITDA Growth Rate is 14.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is McKesson (MEX:MCK) Overvalued in 2026?
Based on GuruFocus' analysis, McKesson stock appears to be overvalued.
The current stock price of MXN15,800.00 is trading 6.9% above its estimated GF Value™ of MXN14,775.99.
GuruFocus considers McKesson to be Fairly Valued.
Key valuation signals for MEX:MCK:
3-Year EBITDA Growth Rate: 14.40% (near median its 10-year median of 15.40)
GF Value™: MXN14,775.99 vs. price of MXN15,800.00 (6.9% above fair value)
Industry Position: 166.7% above the Medical Distribution median (#33 of 105)
No single metric tells the full story. See the MEX:MCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
76GF Score
Get the complete analysis for MEX:MCK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MCK has been successfully added to your 
